Back to top
more

Inari Medical (NARI)

(Delayed Data from NSDQ)

$49.65 USD

49.65
574,532

+2.12 (4.46%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $49.66 +0.01 (0.02%) 4:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Inari Medical (NARI) Q2 Earnings Miss, Revenues Increase Y/Y

Inari Medical's (NARI) second-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.

Inari Medical, Inc. (NARI) Reports Q2 Loss, Tops Revenue Estimates

Inari Medical (NARI) delivered earnings and revenue surprises of -156.25% and 1.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?

DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect growth in the Wellspect Healthcare business and Orthodontic segment amid foreign exchange headwinds.

Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?

Revvity's (RVTY) second-quarter results are likely to reflect strong performance in the Diagnostics segment.

Lower Volume Likely to Hurt GE HealthCare's (GEHC) Q2 Earnings

GE HealthCare's (GEHC) second-quarter results are likely to witness declining segmental revenues in imaging, ultrasound and patient care. The bottom-line results may reflect better pricing.

Factors Setting the Tone for Ecolab's (ECL) Q2 Earnings

Ecolab's (ECL) second-quarter results are likely to reflect continued segmental strength.

Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Inari Medical (NARI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CGM Sensor Demand Likely to Drive DexCom (DXCM) Q2 Earnings

DexCom's (DXCM) second-quarter 2024 results are likely to reflect rising volumes across all channels.

Intuitive Surgical (ISRG) Hits All-Time High: Will It Go Higher?

Intuitive Surgical (ISRG) reported robust quarterly performance last week, and its shares touched an all-time high. Will the company's fundamentals support further upside?

What's in Store for West Pharmaceutical (WST) in Q2 Earnings?

West Pharmaceutical's (WST) second-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

Here's Why You Should Retain Inari Medical (NARI) for Now

Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.

Veracyte (VCYT) Up 8.4% Since Last Earnings Report: Can It Continue?

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Inari's (NARI) Expanding Product Portfolio Offsets Competition

Inari's (NARI) VTE products are driving its top line on the back of robust adoption. The company is expanding in additional indications to fuel growth and fight competition.

Inari Medical (NARI) Sues Truvic on Patent Infringement

Inari Medical (NARI) files a patent infringement lawsuit against Imperative Care and its subsidiary Truvic over intentionally copying and overlapping the designs of Inari Medical's products.

Here's Why You Should Retain Inari Medical (NARI) for Now

Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.

Inari Medical (NARI) Q1 Earnings Miss Estimates, OpEx Rises

Inari Medical's (NARI) first-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the companies continue to incur operating losses.

Inari Medical, Inc. (NARI) Reports Q1 Loss, Tops Revenue Estimates

Inari Medical (NARI) delivered earnings and revenue surprises of -136.36% and 3.53%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

What's in Store for These 5 Medical Device Stocks in Q1 Earnings?

Here is a sneak peek into how the five medical device stocks, SYK, GEHC, ECL, NARI and MMSI, might fare in their quarterly results slated to be released tomorrow.

Why You Should Retain Inari Medical (NARI) Stock for Now

Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.

Inari Medical (NARI) Up 4% Since Last Earnings Report: Can It Continue?

Inari Medical (NARI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Inari Medical's (NARI) ClotTriever Improves Patient Outcome

Inari Medical (NARI) announces two-year interim results from the CLOUT registry, which shows a significant improvement in patient's post-thrombotic syndrome and lower rethrombosis-related events.

Reasons to Retain Inari Medical (NARI) in Your Portfolio Now

Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, its dependency on the adoption of products is a concern.

Inari Medical (NARI) Q4 Earnings Improve Y/Y, Gross Margin Down

Inari Medical's (NARI) fourth-quarter earnings miss, while sales match estimates. Gross margin improves while the company incurs losses at the operating level.

Idexx Laboratories (IDXX) Q4 Earnings and Revenues Top Estimates

Idexx (IDXX) delivered earnings and revenue surprises of 9.43% and 1.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?